Marc Cluzel
Chairman en MORPHOSYS AG .
Fortuna: 599 646 $ al 29/02/2024
Perfil
Founder of C&F Consulting, Marc Cluzel currently is Chairman-Supervisory Board of MorphoSys AG.
He is also on the board of Moleac Pte Ltd.
and Griffon Pharmaceuticals, Inc.
Dr. Cluzel previously held the position of Executive Vice President-Research & Development at Sanofi and Chairman & Chief Executive Officer for Sanofi-Aventis Recherche et Développement SA (a subsidiary of Sanofi) and Executive Vice President-Product Development at HUYA Bioscience International LLC.
Dr. Cluzel received a doctorate from Université de Montpellier and a doctorate from Université de Montpellier.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
MORPHOSYS AG
0.02% | 16/02/2024 | 8 525 ( 0.02% ) | 599 646 $ | 29/02/2024 |
Cargos activos de Marc Cluzel
Empresas | Cargo | Inicio |
---|---|---|
MORPHOSYS AG | Chairman | 17/05/2018 |
Moleac Pte Ltd.
Moleac Pte Ltd. Pharmaceuticals: MajorHealth Technology Moleac Pte Ltd. develops and distributes biopharmaceutical products. It operates as a bio-pharmaceutical company that develops new medicines for the unmet needs of patients suffering from neurological, cardio-vascular and aging conditions. The firm's flagship product NeuroAiD, helps patients recover faster and better from stroke disabilities. The company was founded by David Picard and Marc Vasseur in 2003 and is headquartered in Singapore. | Director/Board Member | - |
Griffon Pharmaceuticals, Inc.
Griffon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Griffon Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products. The private company is based in Montréal, Canada. | Director/Board Member | - |
Antiguos cargos conocidos de Marc Cluzel.
Empresas | Cargo | Fin |
---|---|---|
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 02/01/2012 |
Sanofi-Aventis Recherche et Développement SA
Sanofi-Aventis Recherche et Développement SA Miscellaneous Commercial ServicesCommercial Services Sanofi-Aventis Recherche et Développement SA is a pharmaceutical company based in Chilly-Mazarin, France. Part of Sanofi, Sanofi-Aventis Recherche et Développement SA is a French company that focuses on delivering medicines and vaccines for millions of people around the world. The private company's R & D teams work closely with patient communities affected by rare hematological disorders to offer them effective and innovative therapeutic care. Find out more about rare hematological disorders in R&D. The company was founded in 1900. Lionel Joël Bascles has been the CEO of the company since 2018. | Chief Executive Officer | 01/01/2011 |
SANOFI | Chief Tech/Sci/R&D Officer | 01/01/2010 |
C&F Consulting | Founder | - |
Formación de Marc Cluzel.
Université de Montpellier | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
SANOFI | Health Technology |
MORPHOSYS AG | Health Technology |
Empresas privadas | 5 |
---|---|
Moleac Pte Ltd.
Moleac Pte Ltd. Pharmaceuticals: MajorHealth Technology Moleac Pte Ltd. develops and distributes biopharmaceutical products. It operates as a bio-pharmaceutical company that develops new medicines for the unmet needs of patients suffering from neurological, cardio-vascular and aging conditions. The firm's flagship product NeuroAiD, helps patients recover faster and better from stroke disabilities. The company was founded by David Picard and Marc Vasseur in 2003 and is headquartered in Singapore. | Health Technology |
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |
Sanofi-Aventis Recherche et Développement SA
Sanofi-Aventis Recherche et Développement SA Miscellaneous Commercial ServicesCommercial Services Sanofi-Aventis Recherche et Développement SA is a pharmaceutical company based in Chilly-Mazarin, France. Part of Sanofi, Sanofi-Aventis Recherche et Développement SA is a French company that focuses on delivering medicines and vaccines for millions of people around the world. The private company's R & D teams work closely with patient communities affected by rare hematological disorders to offer them effective and innovative therapeutic care. Find out more about rare hematological disorders in R&D. The company was founded in 1900. Lionel Joël Bascles has been the CEO of the company since 2018. | Commercial Services |
C&F Consulting | |
Griffon Pharmaceuticals, Inc.
Griffon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Griffon Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products. The private company is based in Montréal, Canada. | Health Technology |